Excellthera and Ossium Health Announce a Collaboration to Advance Their Technologies and Platforms to Improve Human Health – GlobeNewswire
stemadminBenefits Of Stem CellsNo comments

MONTREAL, April 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell and molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, and Ossium Health, a therapeutics company harnessing the power of stem cell science to improve treatment for patients with blood and immune diseases, announced today a collaboration agreement to evaluate and advance opportunities to combine their capabilities to further the goal of improving human health. The collaboration plans to evaluate and advance opportunities to employ adult stem cells from deceased donors from Ossium Healths first-in-the-world bone marrow bank in conjunction with ExCellTheras ECT-001 cell expansion and rejuvenation technology, comprised of the UM171 small molecule and an optimized culture system, to treat blood cancers, improve solid organ tolerization and repair damage from radiation. There is deep alignment between ExCellThera and Ossiums biotechnology platforms

Read more
How UFC Legends, Super Bowl Champions And More Use Stem Cell Therapy To Improve Their Quality of Life – Maxim
stemadminBenefits Of Stem CellsNo comments

Former UFC light heavyweight champion and BioXcellerator client Chuck Liddell Getty Images Presented by BioXcellerator I'm very lucky that I'll be able to tell my kids that if you ever face a serious injury or problem in the future I can provide you with a solution that might not involve normal medicine, that could heal or help you get back to where you need to be, explains Michael Alexander, Chief Marketing Officer for BioXcellerator.

Read more
Scientists Just Bioprinted a Pancreas That Could End Diabetes – Interesting Engineering
stemadminBenefits Of Stem CellsNo comments

A company recently developed a novel system capable of printing biological tissue in a blindingly fast 30 seconds creating a possible means of bringing an end to diabetes, according to a blog post shared on the Ecole Polytechnique Federale de Lausanne's (EPFL's) official website. Called Readily3D, the company's technology has seen widespread use in a large-scale European project to build a living model of the human pancreas which could also provide a safe alternative for testing new drugs

Read more
bluebird bio Provides Update on Severe Genetic Disease Programs and Business Operations – Business Wire
stemadminBenefits Of Stem CellsNo comments

CAMBRIDGE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disease (SCD) (bb1111), the companys decision to withdraw ZYNTEGLO (betibeglogene autotemcel, beti-cel) for transfusion-dependent -thalassemia (TDT) from the German market and a targeted reshaping of its workforce intended to enable the company to advance its late-stage gene therapy programs. The case of MDS reported in February in a patient from Group C of the Phase 1/2 HGB-206 study of LentiGlobin gene therapy for SCD has been further assessed following the review of results from additional tests.

Read more
Stem Cell Therapy Market with Impact of COVID-19, Top Companies, Emerging Trends, Demand Analysis, Future Opportunity Outlook 2027 The Courier – The…
stemadminBenefits Of Stem CellsNo comments

Stem Cell Therapy Market is valued at USD 9.32 Billion in 2018 and expected to reach USD 16.51 Billion by 2025 with the CAGR of 8.5% over the forecast period. Rising prevalence of chronic diseases, increasing spend on research & development and increasing collaboration between industry and academia driving the growth of stem cell therapy market.

Read more

Theme: Illdy.